Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

NCT02320032 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02320032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02320032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
April 30, 2016
Enrollment
140 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia